Duloxetine Does Not Significantly Interfere with DAT Scan Results
Duloxetine (Cymbalta) does not meaningfully affect dopamine transporter (DAT) scan results and does not need to be discontinued prior to imaging. The drug's mechanism and pharmacology indicate minimal direct interaction with dopamine transporters that would confound scan interpretation.
Mechanism and Rationale
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that primarily inhibits serotonin and norepinephrine reuptake, with only weak dopamine reuptake inhibition 1. The FDA label explicitly states that duloxetine "has no significant affinity for dopaminergic...receptors in vitro" and is "a less potent inhibitor of dopamine reuptake" compared to its effects on serotonin and norepinephrine 1.
Why This Matters for DAT Scans
DAT scans (ioflupane I-123 SPECT/CT) work by binding to presynaptic dopamine transporters to demonstrate loss of dopaminergic neurons in Parkinsonian syndromes 2. The scan differentiates:
- Parkinsonian syndromes (PD, MSA, PSP, CBD) - showing decreased striatal uptake
- Essential tremor and drug-induced tremor - showing normal uptake
The key concern would be if duloxetine competitively blocked the radiotracer from binding to DAT. However, duloxetine's weak dopamine transporter affinity makes this clinically insignificant.
Evidence from Related Compounds
Research on toludesvenlafaxine, a triple reuptake inhibitor with stronger DAT binding than duloxetine, showed only modest DAT occupancy rates of approximately 8% in humans at therapeutic doses 3. Since duloxetine has even weaker dopamine reuptake inhibition than this triple reuptake inhibitor, its DAT occupancy would be negligible and unlikely to interfere with scan interpretation.
Important Clinical Caveat
One critical exception exists: A case report documented duloxetine unmasking subclinical Parkinson's disease by precipitating parkinsonian symptoms 4. This occurred through indirect mechanisms (possibly 5-HT2 receptor-mediated inhibition of dopamine release), not through direct DAT binding.
Clinical implication: If a patient on duloxetine develops parkinsonian symptoms and undergoes DAT scanning, the scan will still accurately demonstrate underlying dopaminergic deficiency if present. The duloxetine may have unmasked the condition but does not interfere with the diagnostic accuracy of the scan itself.
Practical Recommendation
- Continue duloxetine during DAT scan scheduling and imaging
- No washout period required
- Interpret scan results normally
- If parkinsonian symptoms are present in a patient taking duloxetine, consider that the drug may have unmasked underlying disease rather than causing false-positive imaging findings
The ACR Appropriateness Criteria make no mention of duloxetine or SNRIs as interfering medications for DAT scans 2, further supporting that discontinuation is unnecessary.